louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03690167: Investigation of the Effects of CGF and A-PRF on Pain, Edema and Trismus After Impacted Lower Third Molar Surgery
Official title: Clinical Investigation of the Effects of Concentrated Growth Factor (CGF) and Advanced Platelet Rich Fibrin (A-PRF) on Pain, Edema and Trismus After Impacted Lower Third Molar Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trismus
Edema
Pain
Post-Op Complication
Lead sponsor: T.C. ORDU ÜNİVERSİTESİ
Sponsor class: OTHER
First posted: 2018-10-01
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this case-control intervention study is to explore the effectiveness of Concentrated Growth Factor (CGF) and Advanced Platelet Rich Fibrin (A-PRF) on Pain, Edema and Trismus After Impacted Lower Third Molar Surgery

Detailed description: In the present study, 75 patient, whose ages ranged between 18-30 and have an impacted lower third molar which is in vertical or mesiyoangular position and has class I and II ramus relationship and class B and C depth, will included. 75 patient will divided randomly into three groups as CGF, A-PRF and Control. After third molar surgery CGF and A-PRF will prepared and applied to the extraction sockets in CGF and A-PRF groups. nothing will applied to the control group. Post operative pain, edema and trismus will measured at 2nd and 7th days.

Eligibility criteria: Inclusion Criteria:

* Patients presenting asymptomatic impacted lower third molar tooth in the vertical or mesioanguler position according to the Winter classification, Class I and II ramus relation and class B and C depth according to Pell-Gregory classification
* Patients between the ages of 18-30,
* Non-smokers,
* Patients with ASA I status

Exclusion Criteria:

* Who does not want to be volunteer for the study,
* Do not comply with post-operative recommendations,
* Operation lasting more than 30 minutes,
* During pregnancy or lactation,
* Have a chronic systemic disorder that may affect healing.
* Unable to cooperate,
* Post-operative infection,
* Patients with pericoronitis

Primary outcomes:
measure: Edema-amount change of swelling
timeFrame: Baseline, 2nd and 7th days
Secondary outcomes:
measure: Trismus- degree of change (limitation) in maximum mouth opening
timeFrame: Baseline, 2nd and 7th days
measure: Post operative Pain: visual analog (VAS) scale
timeFrame: 6th and 24th hours, 2nd and 7th days
measure: Post-operative symptom severity (PoSSe) scale
timeFrame: Post operative 7th day
Other outcomes:
Locations:
city: Ordu
country: Turkey
facility: Ordu University
Study officials:
affiliation: T.C. ORDU ÜNİVERSİTESİ
name: Damla Torul, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01386567: A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
Official title: A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypogonadism
Low Testosterone
Keywords: hypogonadism
low testosterone
low T
Lead sponsor: Repros Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2011-07-01
Enrollment: 48
Sex: MALE
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the continued effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism who have completed protocol ZA-203. Men will be allowed to choose Androxal (enclomiphene citrate) or Testim (topical testosterone) at the beginning of the study. All men on Androxal will start at 12.5 mg and will be allowed to up titrate to 25 mg if an inadequate response is exhibited at the lower dose.


Eligibility criteria: Inclusion Criteria:

* Successful completion of ZA-203
* Ability to understand and provide written informed consent
* Agreement to use a condom, and with a fertile female partner, another form of contraception
* Agreement to provide semen samples in the clinic

Exclusion Criteria:

* Any condition which, in the opinion of the Investigator, would make the Subject an unsuitable candidate for enrollment in the study

Primary outcomes:
measure: Change in testosterone comparing Androxal to Testim
timeFrame: 1 year
Secondary outcomes:
measure: Change in leuteinizing hormone and follicle stimulating hormone comparing Androxal (enclomiphene citrate) to Testim (topical testosterone)
timeFrame: 1 year
measure: Changes in sperm parameters from baseline comparing Androxal (enclomiphene citrate) to Testim (topical testosterone)
timeFrame: 1 year
Other outcomes:
Locations:
city: Garden Grove
country: United States
state: California
city: Sacramento
country: United States
state: California
city: San Diego
country: United States
state: California
city: Las Vegas
country: United States
state: Nevada
city: Las Vegas
country: United States
state: Nevada
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
Study officials:
References:
Clinical trial NCT06500767: Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening Programs
Official title: Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Physiological Stress
HPV Infection
Papilloma Viral Infection
Lead sponsor: University of Turin, Italy
Sponsor class: OTHER
First posted: 2024-07-15
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All the patients accessing our Colposcopy service from Prevenzione Serena program with an altered pap smear or a two-times positive HPV test

Brief summary: The communication of an altered Pap smear or positive HPV test has a strong impact on patients on a psychological level. HPV positive women are more likely to have higher level of stress, anxiety, depression and impaired sexual life.

The examiner want to establish this impact through different surveys (DASS-21 (Depression Anxiety Stress Scales); PCL-5 (Posttraumatic Stress Disorder Checklist); DTS (Dyadic Trust Scale), CDDQ (Cervical Dysplasia Distress Questionnaire) and MPI (Match Patient Inventory) from the moment the patient receives the news until after completing treatment for her intraepithelial neoplasia.


Eligibility criteria: Inclusion Criteria:

* patients accessing our Colposcopy service from Prevenzione Serena program with an altered pap smear or a two-times positive HPV test
* patients with biopsy result of HSIL
* ability to fill in surveys via e-mail

Exclusion Criteria:

* previous access in our Colposcopy service
* patients not enrolled in Prevenzione Serena
* pregnant patients
* inability to fill in surveys via email
* partial or total language barrier
* denied consent to participate

Primary outcomes:
measure: DASS-21 (Depression Anxiety Stress Scales).
timeFrame: 3 to 6 months
measure: PCL-5 (Posttraumatic Stress Disorder Checklist);
timeFrame: 3 to 6 months
measure: DTS (Dyadic Trust Scale)
timeFrame: 3 to 6 months
measure: CDDQ (Cervical Dysplasia Distress Questionnaire)
timeFrame: 3 to 6 months
measure: MPI (Match Patient Inventory)
timeFrame: 3 to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Turin
country: Italy
facility: Ospedale Sant'Anna
state: TO
Study officials:
References:
Clinical trial NCT01058967: Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims
Official title: UTHSC-H Proposal for Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Major Trauma Patients
Keywords: Code III trauma (highest acuity)
Life Flight aeromedical ambulance service
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: SonoSite, Inc.
First posted: 2010-01-29
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have experienced a major traumatic injury highest acuity trauma activation (Code III status) transported from scene to hospital via Life Flight (hospital aeroambulance service)

Brief summary: The purpose of this study is to investigate the use of ultrasound by aeromedical prehospital providers.

Detailed description: This study will be divided into three parts. The first portion involves the education/inservices of the aeromedical prehospital providers to document the knowledge and skills necessary to perform and interpret eFAST exams using ultrasound pre hospitalization.

The second portion involves testing the logistics of utilization of prehospital ultrasound. Data will be collected by the participating aeromedical prehospital providers to rate the durability of the equipment, difficulty in preforming the eFAST exam, interference with other actions and ability of retention of images.

The third portion will involve the aeromedical prehospital providers performing the eFAST exam using the ultrasound prehospital and comparing their findings with the gold standard exam, CT scan, while patient is in the emergency department.

Eligibility criteria: Inclusion Criteria:

* Code 3 trauma activation Admitted directly from scene Transported via Life Flight (aeromedical ambulance)

Exclusion Criteria:

* transfer from outside hospital

Primary outcomes:
measure: The primary outcome for this study is to determine if the aeromedical prehospital providers are able to accurately and rapidly perform and interpret eFAST exams in major trauma victims.
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Memorial Hermann Hospital - Medical Center
state: Texas
Study officials:
affiliation: UTHSC-Houston
name: Greg Press, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Press GM, Miller SK, Hassan IA, Alade KH, Camp E, Junco DD, Holcomb JB. Prospective evaluation of prehospital trauma ultrasound during aeromedical transport. J Emerg Med. 2014 Dec;47(6):638-45. doi: 10.1016/j.jemermed.2014.07.056. Epub 2014 Oct 1.
Clinical trial NCT01117467: Factors Affecting Medical Student Learning in Simulation Scenarios
Official title: Factors Affecting Medical Student Learning in Simulation Scenarios
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Learning
Keywords: Simulation
Learning
Medical Students
Empathy
Anxiety
Lead sponsor: University of Oxford
Sponsor class: OTHER
First posted: 2010-05-05
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Simulation is used to teach undergraduate and postgraduate healthcare professionals, however it is not known how best to use this resource. Using qualitative methods, this study aims to investigate how medical students learn during simulation scenarios and will compare students who are paired with peers with those who are solo during their scenarios. Video and audio data from simulations will be collected and analysed with anxiety and empathy questionnaire data and semi-structured interviews.

Detailed description: Medical students attending a simulation day will either perform their simulation paired with another student from the group or solo. Video data from the scenario and audio data from the feedback session will be retained. One week later students will perform a second scenario and the feedback following this will be retained. Students will also have a semi-structured interview and complete anxiety and empathy questionnaires.

Eligibility criteria: Inclusion Criteria:

* All final year medical students at the study university who are allocated to attend the anaesthesia special study module

Exclusion Criteria:

* Non-English speakers
* Visiting students who will be unable to complete the study
* Students who refuse to participate

Primary outcomes:
measure: Learning during simulation scenario as measured qualitatively
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: University of Oxford
state: Oxfordshire
Study officials:
affiliation: University of Oxford
name: Imogen Davies, MB BCh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000267: Risperidone Treatment in Dually-Diagnosed Individuals - 2
Official title: Risperidone Treatment in Dually-Diagnosed Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: New York State Psychiatric Institute
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Side effects
measure: Craving
measure: Drug use
measure: Psychiatric symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
affiliation: New York State Psychiatric Institute
name: Herbert Kleber, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01238367: A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
Official title: Multi-centre, Open-label, Non-randomised Single Dose Trial Investigating the Pharmacokinetics of N8 in Japanese Subjects With Haemophilia A
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Congenital Bleeding Disorder
Haemophilia A
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2010-11-10
Enrollment: 6
Sex: MALE
Minimum age (years): 12
Maximum age (years): 66
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Japan. The aim of this clinical trial is to investigate the pharmacokinetics (the effect of the investigated drug on the body) and safety of turoctocog alfa (recombinant factor VIII (N8)) in Japanese subjects with haemophilia A.


Eligibility criteria: Inclusion Criteria:

* Japanese subjects who have completed NN7008-3543
* No detectable inhibitors to factor VIII

Exclusion Criteria:

* Congenital or acquired coagulation disorders other than haemophilia A
* Planned surgery during the trial period
* Receipt of any investigational drug other than recombinant factor VIII (N8) within 30 days of trial product administration

Primary outcomes:
measure: Area under the curve
timeFrame: Infusion, 30 minutes
measure: Incremental recovery
timeFrame: Infusion, 30 minutes
measure: In vivo t1/2
timeFrame: Infusion, 30 minutes
measure: Total clearance (CL)
timeFrame: Infusion, 30 minutes
Secondary outcomes:
measure: Maximal concentration
timeFrame: at 15 minutes
measure: Area under the curve
timeFrame: from time zero to last
measure: Number of adverse events
timeFrame: from day -1 to day 3 (end of trial)
Other outcomes:
Locations:
city: Itabashi-ku, Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
city: Kashihara-shi, Nara
country: Japan
facility: Novo Nordisk Investigational Site
city: Maebashi-shi, Gunma
country: Japan
facility: Novo Nordisk Investigational Site
city: Shinjuku-ku, Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
city: Shizuoka-shi, Shizuoka
country: Japan
facility: Novo Nordisk Investigational Site
city: Suginami-ku, Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Jimenez-Yuste V, Lejniece S, Klamroth R, Suzuki T, Santagostino E, Karim FA, Saugstrup T, Moss J. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight(R)), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9. doi: 10.1111/jth.12816. Epub 2015 Feb 13.
Clinical trial NCT00772967: A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)
Official title: A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen and Ultracet in a Walking Model of Osteoarthritis Knee Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoarthritis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-10-15
Enrollment: 22
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This study will evaluate a walking model of osteoarthritis for use in testing of new therapeutic agents. The primary hypothesis is that participants treated with Naproxen or Ultracet will have lower Pain Intensity (PI) than those treated with Placebo during self-paced walks on Day 3 of treatment.


Eligibility criteria: Inclusion Criteria:

* Has osteoarthritis of the knee and primary source of pain is knee
* Females must not be pregnant or nursing and must agree to use birth control throughout the study
* Is willing to limit alcohol and caffeine intake
* Is willing to abstain from smoking during study visits
* Must be able to walk on a treadmill at a pace of at least 1 mile/hour

Exclusion Criteria:

* Has a medical/arthritic disease that would interfere with evaluation
* Is unable to take naproxen or Ultracet
* Has congestive heart failure or angina
* Has a history of stroke
* Has a history of uncontrolled high blood pressure
* Has a history of cancer
* Regularly uses a walker or cane

Primary outcomes:
measure: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3
timeFrame: Baseline and Day 3
Secondary outcomes:
measure: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 1
timeFrame: Baseline and Day 1
measure: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 1
timeFrame: Baseline and Day 1
measure: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to High-paced Walks on Day 3
timeFrame: Baseline and Day 3
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Peeva E, Beals CR, Bolognese JA, Kivitz AJ, Taber L, Harman A, Smugar SS, Moskowitz RW. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis Cartilage. 2010 May;18(5):646-53. doi: 10.1016/j.joca.2009.12.008. Epub 2010 Feb 6.
Clinical trial NCT03428867: Register Study of the Neoadjuvanten Treatment by Patients With Rectumcarcinoma
Official title: Phase II Studie Zur Neoadjuvanten Trimodalen Hyperthermen Radiochemotherapie Des Tief Sitzenden Rektumskarzinoms im Stadium UICC II + III
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Feasibilitystudy
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2018-02-12
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with rectumcarcinoma stage UICC II+III

Brief summary: goal of this study is to check the effecivity, feasibility and toxicity of the chemoradiotherapy and hyperthermia

Detailed description: Radiation: 5x1,8Gy until 50,4 Gy Hyperthermia: 2x/week

Chemotherapy:

neoadjuvant= day 1-5 and day 29-33 5FU 1000mg/m2 adjuvant = 4 Cycles 5FU 500mg/m2 all 4 weeks

Eligibility criteria: Inclusion Criteria:

adenocarcinoma until 10 cm until ano UICC II+III 18-80 years old ECOG PS 0-2 Informed Consent

Exclusion Criteria:

cardiac insufficiency last 6 month heartattack nodal AV pressure III° hip prothesis cardiac pacemaker others contraindikations against the therapie radiation of pelvis chronic gestrointestinal desaese gestation or lactation previous radiotion pelvis previous Chemotherapie second carcinoma beside baslioma infiltation in analarea

Primary outcomes:
measure: remission
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
state: Baden Württemberg
Study officials:
affiliation: University Hospital Tuebingen
name: Daniel Zips, Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01139567: Tissue Perfusion and Blood Flow Monitoring Technology
Official title: Tissue Perfusion and Blood Flow Monitoring Technology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Wounds and Injuries
Keywords: Diabetic Wounds
Hyperbaric Oxygen
Laser Speckle Imaging
Hyperbaric Oxygenation
Lead sponsor: CW Optics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institutes of Health (NIH)
name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2010-06-08
Enrollment: 56
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients who have chronic lower extremity wounds will be recruited from the patient population at the Chippenham and Johnston-Willis Medical Center (CJW) for enrollment in the study.

Brief summary: The purpose of this study is to investigate the safety and efficacy of an optical device designed and developed to quantitatively monitor blood flow velocity of wound sites. The hypothesis is that the blood flow velocity of the wound site will provide critical information on the efficacy of hyperbaric oxygen therapy.


Eligibility criteria: Inclusion Criteria

* Subjects age 21 or older with the following types of wounds and who are able to comply with the study requirements:

  * neuropathic diabetic foot ulcer
  * soft tissue radiation necrosis
  * crush injury
  * compromised/failed skin grafts and flaps
* Subjects must have signed the Informed Consent Forms.

Exclusion Criteria

* Subjects who are not candidates for HBO therapy for any reason, including but not limited to: untreated pneumothorax, uncontrolled congestive heart failure, seizure disorder, neoplastic tumors, claustrophobia (for those in the HBO Group).
* Female subjects who are pregnant or nursing.
* Anyone who is unable to give written informed consent.
* Subjects with end-stage renal disease or who require peritoneal or hemodialysis.
* Subjects with current malignancies.

Primary outcomes:
measure: Effectiveness of blood flow velocity measurements of wound sites to assess tissue viability with a novel optical device. Comparison between the responses of patients treated with hyperbaric oxygen therapy and those treated by other means will be made.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Chippenham and Johnston-Willis Medical Center
state: Virginia
Study officials:
References: